SCHEDULE: Dogwood Therapeutics: Major Shareholder Conversion

Sealbond Limited and Conjoint Inc. convert preferred stock into common stock, significantly increasing their beneficial ownership in Dogwood Therapeutics to 73.4% and 9.6% respectively.

Summary

• Sealbond Limited and Conjoint Inc. (Reporting Persons) converted their Series A and Series A-1 Preferred Stock into Common Stock on November 21, 2025.
• This conversion followed stockholder approval and a waiver of the 19.99% beneficial ownership limitation.
• Sealbond received 21,610,950 shares of Common Stock, and Conjoint received 2,842,638 shares of Common Stock.
• Sealbond now beneficially owns 21,822,333 shares, representing 73.4% of Dogwood Therapeutics' Common Stock.
• Conjoint now beneficially owns 2,842,638 shares, representing 9.6% of Dogwood Therapeutics' Common Stock.
• CK Life Sciences Int'l., (Holdings) Inc. is the indirect parent of Sealbond and Conjoint, beneficially owning 24,664,971 shares, or 83.0% of the Common Stock.
• The total outstanding Common Stock after conversion is 29,727,866 shares.
• Registration Rights Agreements were amended to include Conjoint and its shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The conversion simplifies the capital structure and provides liquidity options for major shareholders. However, the high concentration of ownership could be a concern for minority shareholders regarding influence and market liquidity.

Positives

• Conversion of preferred stock to common stock simplifies the capital structure.
• Registration rights agreement provides a mechanism for the reporting persons to potentially liquidate their holdings, offering future liquidity.

Negatives

• The significant concentration of ownership (83.0% by CK Life Sciences Int'l., (Holdings) Inc. through its subsidiaries) could reduce liquidity for other shareholders and limit their influence.

Risks

• Reporting Persons may acquire additional shares or dispose of their beneficially owned shares in the ordinary course of business, potentially impacting market price.
• Reporting Persons may consider extraordinary corporate transactions, such as mergers, reorganizations, or liquidations.
• Potential for changes in the board of directors or management due to the controlling equity ownership position.
• Possible material changes in the company's capitalization, dividend policy, business, or corporate structure.
• Actions that may impede the acquisition of control of the Company by any other person.
• Potential delisting from a national securities exchange or termination of registration.

Future Outlook

The Reporting Persons hold their shares for investment purposes and may acquire or dispose of shares based on market conditions and investment policies. They may also consider various alternative courses of action, including extraordinary corporate transactions, changes in management or board, material changes in capitalization or dividend policy, or actions affecting the company's listing or registration. However, they currently have no plans for control transactions or contested director solicitations.

Management Comments

• Mr. Yu, Deputy Chairman and Executive Director of CK Life Sciences, and Dr. Toh, Vice President, Chief Scientific Officer, and Executive Director of CK Life Sciences, are members of Dogwood's board of directors and may discuss or consider plans or proposals in their fiduciary capacities.

Industry Context

This filing primarily details a significant ownership change within Dogwood Therapeutics, driven by the conversion of preferred stock. It reflects a consolidation of control by a major investor group, which is a company-specific event rather than a broad industry trend. However, such large ownership stakes can influence a company's strategic direction and market perception within its industry.

Corporate Governance

Related Party Transactions

• Sealbond Limited and Conjoint Inc. are subsidiaries of CK Life Sciences Int'l., (Holdings) Inc., making their transactions with Dogwood Therapeutics (where CK Life Sciences executives are directors) related party dealings.
• The conversion of Preferred Stock held by Sealbond and Conjoint into Common Stock.
• The Registration Rights Agreement and its amendment involve Sealbond and Conjoint, who are related parties to Dogwood Therapeutics through CK Life Sciences.

Stakeholder Impact

• Shareholders: Significant increase in beneficial ownership by a controlling group (CK Life Sciences through Sealbond and Conjoint) to 83.0% could reduce the influence of minority shareholders and potentially impact stock liquidity if the controlling group decides to dispose of large blocks of shares. Simplification of capital structure from preferred to common stock.
• Management/Board: The controlling equity ownership position by the Reporting Persons gives them significant power to influence changes in the board of directors or management.

Next Steps

• The Company will file a Form S-1 or S-3 registration statement upon request from holders of Registrable Securities, subject to specified thresholds and conditions.
• Reporting Persons will continue to review their investment in the Company based on various factors.

Key Dates

Recommendation

The filing primarily details a significant ownership consolidation and capital structure simplification. While the conversion of preferred stock to common stock is a positive step for transparency and liquidity for the major shareholders, the resulting high concentration of ownership (83.0% by the CK Life Sciences group) could be a concern for minority shareholders regarding market liquidity and corporate control. There are no new operational or financial performance details to warrant a strong buy or sell. Investors should hold and monitor how the controlling shareholders exercise their influence and any future disposition plans.

Keywords

Dogwood Therapeutics, Sealbond Limited, Conjoint Inc., CK Life Sciences, Schedule 13D, Common Stock, Preferred Stock Conversion, Beneficial Ownership, Registration Rights Agreement, Equity Ownership, Corporate Governance